source
- Merck barred from making subcutaneous Keytruda in 8 European countriesWith the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.BioSpace · 13d ago↗ source
- Cerevance's solengepras cuts Parkinson off-time by 0.6 hours in Phase 3, advancing toward FDA reviewCerevance, a spinout from Takeda, reported that a high 150‑mg dose of its Parkinson's drug solengepras reduced daily "off time" by an average of 0.61 hours compared with placebo in the Phase 3 ARIS…